Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Oregon Technology Today.
Press releases published on May 20, 2025
Dogecoin XRP and Solana Price Prediction: Why Holders Are Flocking to XY Miners for Passive Income?
GlobeNewswire
·
May 20, 2025
Los Angeles, California, May 20, 2025 (GLOBE NEWSWIRE) -- Cryptocurrency markets reacted to the SEC's delayed ETF decision, with XRP, Solana (SOL), and Dogecoin (DOGE) all seeing price volatility. Traders are keeping a close eye on these assets to gauge …
MicroAlgo Inc. Researches Quantum Machine Learning Algorithms to Accelerate Machine Learning Tasks
GlobeNewswire
·
May 20, 2025
shenzhen, May 20, 2025 (GLOBE NEWSWIRE) -- Shenzhen, May. 20, 2025/––MicroAlgo Inc. (the "Company" or "MicroAlgo") (NASDAQ: MLGO), announced that quantum algorithms will be deeply integrated with machine learning to explore practical application scenarios …
Biometric Identity and Access Management Software Solutions Provider BIO-key Announces Two Webcast Investor Presentations: Aegis Capital Thu. May 22 at 11:30am ET and Maxim Group Wed. June 4 at 11am ET
GlobeNewswire
·
May 20, 2025
HOLMDEL, N.J., May 20, 2025 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (Nasdaq: BKYI), an innovative provider of workforce and customer Identity and Access Management (IAM) solutions featuring passwordless, phoneless and tokenless, Identity-Bound …
XRP News: Top 3 Ripple Ecosystem Tokens To Watch Out For In 2025 – XRPTurbo ($XRT), XRPHealthcare (XRPH) & Phoenix (PHNIX)
GlobeNewswire
·
May 20, 2025
TALLINN, Estonia, May 20, 2025 (GLOBE NEWSWIRE) -- As the XRP ecosystem gears up for what could be its most explosive year yet, savvy investors are positioning themselves ahead of the curve and XRPTurbo (XRT) is quickly emerging as a frontrunner in that …
ZenaTech Advances Its US Southeast DaaS Business with a Bolt-On Land Survey Company Acquisition Offer
GlobeNewswire
·
May 20, 2025
VANCOUVER, British Columbia, May 20, 2025 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) ("ZenaTech"), a technology company specializing in AI (Artificial Intelligence) drones, Drone as a Service (DaaS), enterprise SaaS, and …
XRP News: XpFinance Fills 20% Of Presale Softcap, Set To Release First Look Of Lending & Borrowing Platform On XRPL
GlobeNewswire
·
May 20, 2025
VILNIUS, Lithuania, May 20, 2025 (GLOBE NEWSWIRE) -- XpFinance, a decentralized lending and borrowing platform built specifically for the XRP Ledger kicked off its highly anticipated presale and investors are already racing to secure their stake. Within …
Kura Oncology to Participate in Three Upcoming Investor Conferences
GlobeNewswire
·
May 20, 2025
SAN DIEGO, May 20, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that …
Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM
GlobeNewswire
·
May 20, 2025
- In a post-hoc analysis of ATTRibute-CM, acoramidis reduced the annual frequency of CVH due to AF/AFL by 43% compared to placebo and reduced the incidence of new-onset AF/AFL by 17% in the subgroup with no prior history of AF compared to placebo - In the …
Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome
GlobeNewswire
·
May 20, 2025
Company continues to advance QRX003 in late-stage clinical trials in Netherton Syndrome patients Regulatory milestone provides 10 years of market exclusivity in Europe upon approval ASHBURN, Va., May 20, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. …
Incannex Healthcare Inc. Executes Strategic Cancellation of 50.4% of Series A Warrants, Significantly Reducing Potential Dilution
GlobeNewswire
·
May 20, 2025
NEW YORK and MELBOURNE, Australia, May 20, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company pioneering the development of combination drug therapies, today announced …
Aptose Announces Dosing of First Patient with 120 mg of Tuspetinib in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy after Dose Escalation Decision by Safety Review Committee
GlobeNewswire
·
May 20, 2025
TUS+VEN+AZA triplet achieves complete remissions (CRs) and minimal residual disease (MRD)-negativity with favorable safety in newly diagnosed AML patients Completed 40 mg and 80 mg TUS dose cohorts; no prolonged myelosuppression or dose-limiting toxicities …
Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease
GlobeNewswire
·
May 20, 2025
– Rapid, deep, and durable reductions in high-sensitivity C-reactive protein (hs-CRP) through Day 90 achieved across all pacibekitug arms with high statistical significance as compared to placebo (p<0.0001 for all arms) – – Pacibekitug becomes the first …
CryptoVirally Unveils Revamped Website and Innovative Campaign Planner to Streamline Web3 Marketing
GlobeNewswire
·
May 20, 2025
Bucharest, Romania, May 20, 2025 (GLOBE NEWSWIRE) -- CryptoVirally, a leading crypto-exclusive marketing agency, proudly announces the launch of its redesigned website, aimed at simplifying access to comprehensive Web3 marketing services for blockchain …
PrimeXBT Wins Best Crypto Trading Platform and Best Cryptocurrency Broker Awards
GlobeNewswire
·
May 20, 2025
Castries, Saint Lucia, May 20, 2025 (GLOBE NEWSWIRE) -- PrimeXBT, a trusted multi-asset broker known for its client-centric approach to trading, has been named Best Crypto Trading Platform 2025 by the Global Crypto Awards. This international recognition …
Arctic Wolf 2025 Trends Report Reveals AI is Now the Leading Cybersecurity Concern for Security and IT Leaders
GlobeNewswire
·
May 20, 2025
EDEN PRAIRIE, Minn., May 20, 2025 (GLOBE NEWSWIRE) -- Arctic Wolf®, a global leader in security operations, today published findings from its State of Cybersecurity: 2025 Trends Report, offering insights from a global survey of more than 1,200 senior IT …
Pasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases
GlobeNewswire
·
May 20, 2025
-- Demonstrates PAS-004’s potential as a differentiated MEK inhibitor for immune-mediated inflammatory diseases such as IBD and ankylosing spondylitis – -- Positions PAS-004 for potential expansion beyond MAPK pathway driven tumors into inflammatory …
atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech’s Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression
GlobeNewswire
·
May 20, 2025
- Positive results show that a single dose of BPL-003, administered adjunctively to SSRIs, produced a rapid and durable antidepressant effect for up to three months after dosing - BPL-003 was well-tolerated and patients were able to be discharged within an …
Upstream Bio Appoints Stacy Price as Chief Technology Officer
GlobeNewswire
·
May 20, 2025
WALTHAM, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced the appointment of Stacy …
Helius to Spotlight Study Confirming Improved Long-Term Outcomes from Adherence to PoNS Therapy® at CMSC Annual Meeting
GlobeNewswire
·
May 20, 2025
NEWTOWN, Pa., May 20, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced it will highlight the results …
I-Mab to Present at Jefferies Global Healthcare Conference
GlobeNewswire
·
May 20, 2025
ROCKVILLE, Md., May 20, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab’s management …